# Genotype → Phenotype Map (Selected Variants)

| Variant (Gene • rsID) | Functional Effect | Expected Clinical Expression |
|---|---|---|
| **COMT Val158Met (COMT • rs4680)** | Met allele → ↓ COMT activity | Slower methylation of catechol estrogens/catecholamines → hyperarousal, slower E2 catechol clearance |
| **CYP1A2 *1F (CYP1A2 • rs762551)** | Inducible isoform | Faster 2-hydroxylation of E2 when induced (e.g., caffeine); sensitive to methyl donor/liver status |
| **CYP3A4*22 (CYP3A4 • rs35599367)** | ↓ Expression/activity | Slower hepatic E2 clearance → higher circulating E2 for longer |
| **CYP3A5*3 (CYP3A5 • rs776746)** | Non-expressor | Shifts clearance burden to CYP3A4; accentuates *22 effect |
| **UGT1A1*28 tag (UGT1A1 • rs887829)** | ↓ Glucuronidation capacity | Impaired E2 metabolite clearance; Gilbert-like pattern possible |
| **SULT1E1 promoter (SULT1E1 • rs3736599)** | ↓ Estrogen sulfation (putative) | Longer active E2 half-life |
| **SULT2A1 (rs2637125)** | Alters DHEA sulfation | Consistent with low DHEAS labs pattern |
| **SHBG (rs6259 / rs12150660 / rs1799941)** | ↑ SHBG alleles | ↓ Free T/E2; higher total with lower bioavailable fraction |
| **CYP19A1 (rs10046 / rs4646 / rs700519 / rs727479)** | Aromatase regulation/activity variants | Modulate aromatase output; rs700519 Arg264Cys may reduce activity |

> Full variant details and references: see `data/analytics/genetics_appendix.md` and `refs/*`.
